Journal News

Move over, DNA. The future is protein

Renae   Crossing
Sept. 20, 2022

In the coming decades, efforts to understand disease will be propelled by building 3D maps of protein arrangements in cells over time, a team of scientists says.

A workshop about the study of proteins on a large scale — proteomics — yielded a perspective piece that is part vision, part plan, recently published in the journal Molecular & Cellular Proteomics.

DNA is like a game plan, explains Neil Kelleher, a researcher at Northwestern University who was involved in the study, and RNA is like the team huddle; it’s what the cell decides to do with the circumstances on the day.

It’s time to watch the game itself. “This is the decade,” Kelleher said.

Maps will show how proteins take different forms over space and time, from milliseconds to years. It’s postgame analysis for cells.
Neil Kelleher et al./MCP
Maps will show how proteins take different forms over space and time, from milliseconds to years. It’s postgame analysis for cells.

Watching the game

“Traditionally, we study one protein or pathway at a time,” the authors write, because “the cell is otherwise too complex.”

That’s like watching one player over time and whom they pass to.

Proteins take multiple forms in a cell after they come off the bench. An electric link between fans and footballers inspires the play that decides a championship. A comment or word from a coach flicks a switch. In the cell, such switches can be as simple as a few atoms added (phosphorus and a trio of oxygens are a popular one). Altered by their circumstances, proteins are like people.

Mapping their shapes over time will be game-changing.

“This could impact all diseases,” said Kristin Burnum–Johnson of Pacific Northwest National Laboratory, first author of the paper.

How will this happen?

Bottoms up, touchdowns

Scientists will tackle this from two directions: bottom-up and top-down. They start with clinical tissue samples, Burnum–Johnson explained.

"For bottom-up approaches, you extract proteins from tissue regions and break them into identifiable peptides (shorter strings of proteins).”

Bottom-up strategies, combined with RNA and metabolite data, will reveal the lineup. Top-down strategies will yield those sweet, sweet action shots.

Kelleher knows about this. The top-down approach, revealing the specific forms proteins take (which RNA sequencing can’t tell you), has become so sensitive that his research recently found 30,000 precise forms of proteins in blood and bone marrow alone. That’s almost 10 times more than in previous studies. There are thousands more cell types for postgame analysis.

Single-minded

Researchers will continue pushing for higher resolution. They’ll need to integrate data, which is not a simple challenge. They’ll need to think beyond stadium walls; the extracellular matrix is rich. Like football and cells alike, consortiums and partnerships will drive the process. The National Institutes of Health wants research gaps to be identified, and private investment is supporting the sequencing of single molecules. These combined efforts remind Kelleher of the Human Genome Project.

The central dogma of biology is DNA to RNA to protein. It’s only natural that scientific research follows the path that is familiar. It’s protein’s turn.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Renae   Crossing

Renae Crossing is a writer and former teacher. She holds a first-class master’s degree in life science from the Hong Kong University of Science and Technology and a first-class master’s in teaching from the University of Melbourne.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Journal News

Catching tau in the act

April 2, 2026

Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.

How copper delivery fuels bacterial respiration
Journal News

How copper delivery fuels bacterial respiration

April 1, 2026

Researchers identify the roles of several proteins in copper homeostasis in the aerobic bacterium Caulobacter vibrioides.

Revealing the glycoproteome of a cancer subtype
Journal News

Revealing the glycoproteome of a cancer subtype

March 31, 2026

Researchers mapped the glycoproteome of extrahepatic cholangiocarcinoma and compared it to intrahepatic tumors. Differences in sugar modifications and immune cell content suggest new biomarkers and guide development of targeted immunotherapies.

Uncovering the mechanisms of a glycosylation disorder
Journal News

Uncovering the mechanisms of a glycosylation disorder

March 27, 2026

Mutations in OGT, an enzyme that adds sugars to proteins, cause a rare neurological disorder. Using proteomics, researchers reveal how OGT interactions with TET proteins may trigger epigenetic changes and early neural defects.

Heat shock proteins as a promising breast cancer therapeutic
Journal News

Heat shock proteins as a promising breast cancer therapeutic

March 25, 2026

Researchers unveiled isoform-specific targets on heat shock protein 90 which may be beneficial in therapeutic development.